Suomi - suomi - Fimea (Suomen lääkevirasto)

medica - riboflavini natrii phosphas,panthenolum,extractum hepatis,ferritetraceminnatrium,strychnini glycerophosphas,nicotinamidum,pyridoxini hydrochloridum,spiritus fortis,coffeinum natrii benzoas - mikstuura - muut yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

terpia bernerin lääketehdas oy - mononatrii phosphas,strychnini nitras,extractum hepatis,extractum saccharomyces medicinalis - mikstuura - toonikumit

Suomi - suomi - Fimea (Suomen lääkevirasto)

zoetis animal health aps - oxytetracycline hydrochloride, polymyxin b sulfate - voide - oksitetrasykliiniä sisältävät yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

galderma nordic ab - amorolfine hydrochloride - lääkekynsilakka - 5 % - amorolfiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

glaxosmithkline consumer healthcare aps - chlorhexidine digluconate - geeli suuonteloon - 1 % - klooriheksidiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

cp-pharma handelsgesellschaft mbh - clenbuterol hydrochloride - siirappi - 25 mikrog/ml - klenbuteroli

Suomi - suomi - Fimea (Suomen lääkevirasto)

le vet. beheer b.v. - clenbuterol hydrochloride - siirappi - 25 mikrog/ml - klenbuteroli

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Euroopan unioni - suomi - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. immuunijärjestelmää on osoitettu 1 viikon kuluttua rihotrakeiitti-, kalicivirus- ja chlamydophila felis -komponenttien ensisijaisesta rokotuskurssista. immuniteetin kesto on yksi vuosi viimeisen (uudelleen) rokottamisen jälkeen.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.